8月27日 - ** 癌症药物开发商CEL-SCI的CVM.A股价在延时交易中暴跌19.5%至10.50美元
** CVM公布了 (link)，拟公开发行股票和预先筹资的认股权证；规模未披露
** 发售所得将用于资助Multikine（其头颈癌治疗方法）的持续开发及其他用途
** ThinkEquity 担任此次发行的独家配售代理
** 根据LSEG的数据，CVM有690万股流通股，市值8970万美元。
** 截至上一交易日收盘，CVM股价年累计上涨8.7%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.